Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic chair resigns after failed takeover bid
14 Nov 2025, 06:43BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.

Bavarian Nordic chair resigns after failed takeover bid
13 Nov 2025, 19:48BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.

Bavarian Nordic shareholders reject private equity takeover bid
6 Nov 2025, 14:06BAVA.CONASDAQ Copenhagen

A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.

Bavarian Nordic deal struggles as vaccine contract boosts value
31 Oct 2025, 13:13BAVA.CONASDAQ Copenhagen

A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.

New EU vaccine deal complicates Bavarian Nordic takeover
31 Oct 2025, 08:21BAVA.CONASDAQ Copenhagen

Bavarian Nordic has secured a new long-term contract to supply the European Union with up to 8 million doses of its smallpox and mpox vaccine over the next four years, the company said Friday.

Private equity lowers Bavarian Nordic takeover threshold
21 Oct 2025, 12:48BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has lowered the minimum shareholder acceptance threshold for its takeover offer for Danish vaccine maker Bavarian Nordic, as it struggles to win enough support for the deal.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic is Planning a Rights Issue of DKK 250-300 Million. The Company Has Convened an Extraordinary General Meeting1 Dec 2009
Bavarian Nordic A/S - Notice convening Extraordinary General Meeting1 Dec 2009
Bavarian Nordic will file for market approval for IMVAMUNE® in Canada30 Nov 2009
Bavarian Nordic A/S issues Financial Calendar for 201026 Nov 2009
US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE® Smallpox Vaccine17 Nov 2009
Bavarian Nordic Enters Conditional Agreement for the Acquisition of Shares and Buy Back of Stock Options in its Subsidiary BN ImmunoTherapeutics Inc. in Order to Obtain 100% Ownership of the Subsidiary11 Nov 2009
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 September 200911 Nov 2009
New and interesting PROSTVAC(TM) data indicate broad therapeutic use in metastatic prostate cancer21 Sept 2009
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such18 Sept 2009
Bavarian Nordic has signed contract with an EU country for the delivery of IMVAMUNE®15 Sept 2009
Bavarian Nordic rejects claim from Helmholtz Zentrum München31 Aug 2009
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 June 200928 Aug 2009
  • Previous
  • 1
  • More pages
  • 55
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 56
  • 57
  • More pages
  • 78
  • Next
  • Filings
    927